背景:SARS-CoV-2与其他呼吸道病毒的并发循环是不可阻挡的,并且代表了临床医生和临床微生物学实验室的新诊断现实。在自动化平台上进行多重分子测试,专注于在单个管中同时检测多种呼吸道病毒,是当前和未来在临床环境中诊断呼吸道感染的有用方法。
方法:研究包括两个时间段:2022年2月至4月,2022年早期,在该国逐步取消COVID-19预防措施的过程中,2022年10月至2023年4月,2022/23年呼吸道感染季节。我们使用多重分子测定法分析了第一阶段的1,918个样本和第二阶段的18,131个呼吸道样本,用于同时检测甲型流感(Flu-A)。乙型流感(Flu-B),人呼吸道合胞病毒(HRSV)和SARS-CoV-2。
结果:2022年初的结果显示,SARS-CoV-2感染占1,267/1,918例(66.1%)。在30/1,918(1.6%)样本中检测到甲型流感,14/1,918(0.7%)样品中的HRSV,和2/1,918(0.1%)个样本中的流感-B。在11/1,267(0.9%)样本中观察到流感A/SARS-CoV-2的共同检测,5/1,267(0.4%)样品中HRSV/SARS-CoV-2的共检测。在2022/23冬季呼吸季节,在1,738/18,131(9.6%)中检测到SARS-CoV-2,628/18,131年甲型流感(3.5%),乙型流感在106/18,131(0.6%),505/18,131(2.8%)样品中的HRSV。有趣的是,共同检测的存在程度与2022年初相似。
结论:结果表明,多重分子方法是同时实验室诊断SARS-CoV-2,Flu-A/B,住院和门诊患者的HRSV。A/B型流感感染,和HRSV发生在COVID-19控制措施解除后不久,因此,预计在COVID-19后期间,各种呼吸道感染和共同检测会强烈复发。
BACKGROUND: The concurrent circulation of SARS-CoV-2 with other respiratory viruses is unstoppable and represents a new diagnostic reality for clinicians and clinical microbiology laboratories. Multiplexed molecular testing on automated platforms that focus on the simultaneous detection of multiple respiratory viruses in a single tube is a useful approach for current and future diagnosis of respiratory infections in the clinical setting.
METHODS: Two time periods were included in the study: from February to April 2022, an early 2022 period, during the gradual lifting of COVID-19 prevention measures in the country, and from October 2022 to April 2023, the 2022/23 respiratory infections season. We analysed a total of 1,918 samples in the first period and 18,131 respiratory samples in the second period using a
multiplex molecular assay for the simultaneous detection of Influenza A (Flu-A), Influenza B (Flu-B), Human Respiratory Syncytial Virus (HRSV) and SARS-CoV-2.
RESULTS: The results from early 2022 showed a strong dominance of SARS-CoV-2 infections with 1,267/1,918 (66.1%) cases. Flu-A was detected in 30/1,918 (1.6%) samples, HRSV in 14/1,918 (0.7%) samples, and Flu-B in 2/1,918 (0.1%) samples. Flu-A/SARS-CoV-2 co-detections were observed in 11/1,267 (0.9%) samples, and HRSV/SARS-CoV-2 co-detection in 5/1,267 (0.4%) samples. During the 2022/23 winter respiratory season, SARS-CoV-2 was detected in 1,738/18,131 (9.6%), Flu-A in 628/18,131 (3.5%), Flu-B in 106/18,131 (0.6%), and HRSV in 505/18,131 (2.8%) samples. Interestingly, co-detections were present to a similar extent as in early 2022.
CONCLUSIONS: The results show that the
multiplex molecular approach is a valuable tool for the simultaneous laboratory diagnosis of SARS-CoV-2, Flu-A/B, and HRSV in hospitalized and outpatients. Infections with Flu-A/B, and HRSV occurred shortly after the COVID-19 control measures were lifted, so a strong reoccurrence of various respiratory infections and co-detections in the post COVID-19 period was to be expected.